
We invite you to engage in an interactive nintely minute roundtable led by EverythingALS consortia of Pharma partners, sensor companies, neurologists, data scientists, regulators and patients to help advance the discovery and implementation of ALS digital biomarkers in clinical trials through our collaborative efforts.
Joining our participatory roundtable, you will be the first to learn about our latest study results on ALS digital biomarkers as well as have the opportunity to hear why major pharmaceutical companies have joined the consortium to partner in EverythingALS research, which will be expanded to include analyzing data from wearables and smartphones.
As always, we approach each roundtable to encourage out-of-the-box thinking, and to kick it off, we have an exciting agenda! Take a look below.
This is an invite only event.
Hosts & Speakers

Agenda
Thursday Sept 25th, 2025
1:00 - 2:00 PM ET   I   10:00 - 11:00 AM PT
10 minutes
10 minutes
10 minutes
10 minutes
10 minutes
10 minutes
Highlights and Announcements
Indu Navar, Founder & CEO, EverythingALS
James Berry, Chief, Division of ALS and MND, Mass General Brigham
Opening Keynote
Hear from a Person Living with ALS
Breaking News: NIH Grant Award for Spanish Speech Study.
Multi-Lingual Endpoint Development in collaboration with NSU.
Dr. Lauren Tabor Gray, PhD, CCC-SLP
Nova Southeastern University (NSU) Health Cathy J. Husman ALS Center
Takeaways: 2025 EverythingALS Digital Endpoints & Biomarker Summit
- 
Embedding Listener’s Effort (LE) as a core endpoint in ALS trials
 - 
From Insights to Intervention: Bridging digital, circuit, and cell-level collaboration with the Allen Brain Institute
 - 
Clinical Trial Ready Cohort: “People with ALS” — reducing screening costs and recruitment delays
 
END OPEN SESSION
Consortia Members’ Breakout
1:40-2:00 PM ET
Collaboration Highlights
Digital endpoints → brain/cell integration → trial-ready cohorts: building a care-to-cure flywheel for ALS
Next steps
Voting on 2025–2026 priorities and alignment of action items






































